Add Yahoo as a preferred source to see more of our stories on Google. Although there are more than 100 conditions that fall under the umbrella term "arthritis," an autoimmune disease called rheumatoid ...

Doctors may order a cyclic citrullinated peptide (CCP) antibody test and other exams to confirm or rule out a rheumatoid arthritis (RA) diagnosis. A positive CCP antibody test doesn’t necessarily mean ...

A rheumatoid factor (RF) test detects rheumatoid factor, a type of antibody (proteins that fight off harmful substances) in your blood. RF antibodies sometimes attack healthy cells and tissues, ...

Dr. Eric Ruderman answers the question: 'X-Rays And Bone Mineral Density Tests?' — -- Question: How are X-rays and bone mineral density tests used to diagnose rheumatoid arthritis? Answer: X-rays ...

Please provide your email address to receive an email when new articles are posted on . Exagen Diagnostics has announced the launch of the first validated blood test to detect anticarbamylated protein ...

Crescendo Bioscience, creators of the Vectra DA blood test to predict the progression of rheumatoid arthritis (RA), is gaining market share in the United States, with its new parent company, Myriad ...

Please provide your email address to receive an email when new articles are posted on . The American College of Rheumatology has added the Vectra blood test, developed by Myriad Genetics, to its list ...

Oct. 28, 2003 (Orlando) -- The presence of antibodies to cyclic citrullinated peptides (CCP) may accurately predict the likelihood of developing rheumatoid arthritis (RA) in patients with recent-onset ...

Rheumatoid arthritis (RA) is a chronic, progressive disease caused by an overactive immune system. RA affects smaller joints in the body as well as larger ones. When there’s the involvement of smaller ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

Precision medicine company Aqtual has secured $31m in a Series B financing round to progress its active chromatin cell-free DNA (cfDNA) platform and launch a rheumatoid arthritis (RA) therapy response ...